Eli Lilly Gains Rights to AI-Discovered Drugs in $2.75B Deal with Insilico
Eli Lilly's $2.75 billion deal with Insilico Medicine now includes rights to develop and sell specific AI-discovered drug candidates, notably those targeting GLP-1 for oral use. This development underscores Lilly’s commitment to AI in drug innovation and signals a move toward more targeted therapies.
· 67d ago
